[Clinical value of the symptom-relieving operation in multimodality therapy of stage IIIB and IV lung cancer].
To explore the clinical value of the symptom-relieving operation in multimodality therapy of stage IIIB and IV lung cancer for rising quality of life and prolonging survival time. The pain incidence rate, fraction of Karnofsky and anesthesia, clinical effect of treatment and survival rate of 29 cases were statistically analysed using SPSS software, in multimodality therapy of stage IIIB and IV lung cancer, before and after symptom-relieving operation. The difference between before and after operation was compared with Chi-Square and t test. The survival rate was calculate with Kaplan-Meier method. The complete remission rate for cases of malignant pleural effusion and pericardial effusion was 100% ( 15/ 15) . The 1-year survival rate was 66. 67%, mean survival time was 13. 81± 1. 61 months, and median survival time was 16. 00 months. The 1-year survival rate of cases with bone metastasis was 20. 0%, mean survival time was 9. 90± 0. 99 months, median survival time was 10. 00 months. After therapy, the pain incidence rate of all patients was decreased from 89. 7% to 34. 5% ( P < 0. 001) ; Karnofsky score was increased from 58. 28 ± 2. 17 to 82. 41± 1. 54( P < 0. 001) ; fraction of anesthesia was decreased from 5. 17± 0. 53 to 1. 45± 0. 38 ( P < 0. 001) . The symptom-relieving operation for metastasis lesion can rise the quality of life, prolong survival time, decrease dependence of anesthetic and analgesic drugs in multimodality therapy of stage IIIB and IV lung cancer.